Trial Profile
A Prospective, Multicenter study to evaluate the efficacy of the salvage therapy with Sofosbuvir, Elbasvir, Grazoprevir and Ribavirin for the treatment of GT3 and GT1/4 HCV Infection in patients who relapsed following DAA treatment including an NS5A inhibitor
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2020
Price :
$35
*
At a glance
- Drugs Elbasvir (Primary) ; Grazoprevir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Dec 2018 New trial record
- 13 Nov 2018 Results (n=30) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases